CHARACTERIZATION OF THE HUMAN PLATELET ENDOTHELIAL-CELL ADHESION MOLECULE-1 PROMOTER - IDENTIFICATION OF A GATA-2 BINDING-ELEMENT REQUIRED FOR OPTIMAL TRANSCRIPTIONAL ACTIVITY
Rj. Gumina et al., CHARACTERIZATION OF THE HUMAN PLATELET ENDOTHELIAL-CELL ADHESION MOLECULE-1 PROMOTER - IDENTIFICATION OF A GATA-2 BINDING-ELEMENT REQUIRED FOR OPTIMAL TRANSCRIPTIONAL ACTIVITY, Blood, 89(4), 1997, pp. 1260-1269
Platelet/endothelial cell adhesion molecule-1 (PECAM-1) is a 130-kD me
mber of the Ig gene superfamily that is expressed on platelets, endoth
elial cells, and certain leukocyte subsets. To examine the factors con
trolling vascular-specific expression of PECAM-1, we cloned the 5'-fla
nking region of the PECAM-1 gene and analyzed its transcriptional acti
vity. 5'-Rapid amplification of cDNA ends (5'-RACE) analysis showed th
at transcription initiation occurred at several closely spaced nearby
sites originating approximately 204 bp upstream from the translation s
tart site. Analysis of the sequence immediately upstream from the tran
scription initiation site (TIS) showed no canonical TATA or CAAT eleme
nts, however an initiator element commonly found in TATA-less promoter
s encompassed the TIS. 5'-serially truncated PECAM-1 promoter segments
cloned in front of a luciferase reporter drove transcription in both
a lineage- and orientation-specific manner. Putative cis-acting contro
l elements present within a 300-bp core promoter included two ets site
s, an Spl site, tandem E-box domains, two GATA-associated sites (CACCC
), an AP-2 binding site, and a GATA element at -24. Mutational analysi
s showed that optimal transcriptional activity required the GATA seque
nce at position -24, and gel-shift assays further showed that the GATA
-2 transcription factor, but not GATA-1, bound to this region of the P
ECAM-1 promoter, Understanding the cis- and transacting factors that r
egulate the tissue-specific expression of PECAM-1 should increase our
understanding of the mechanisms by which vascular-specific gene expres
sion is achieved. (C) 1997 by The American Society of Hematology.